This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



#### Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

## SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRIDIN-2-ONE NUCLEOSIDES

Caroline M. Huntley<sup>a</sup>; Ann S. Cotterill<sup>a</sup>; Jean-Yves Maillard<sup>a</sup>; Jan Balzarini<sup>b</sup>; Claire Simons<sup>a</sup> Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom <sup>b</sup> Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium

Online publication date: 31 March 2001

To cite this Article Huntley, Caroline M., Cotterill, Ann S., Maillard, Jean-Yves, Balzarini, Jan and Simons, Claire (2001) 'SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRIDIN-2-ONE NUCLEOSIDES', Nucleosides, Nucleotides and Nucleic Acids, 20: 4, 731 - 733

To link to this Article: DOI: 10.1081/NCN-100002361 URL: http://dx.doi.org/10.1081/NCN-100002361

#### PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

# SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRIDIN-2-ONE NUCLEOSIDES

Caroline M. Huntley, Ann S. Cotterill, Jean-Yves Maillard, Jan Balzarini, and Claire Simons 1,\*

<sup>1</sup>Medicinal Chemistry and <sup>2</sup>Microbiology Divisions, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, United Kingdom <sup>3</sup>Rega Institute, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium

#### **ABSTRACT**

The synthesis of  $1-(\beta-D-ribofuranosyl)$  pyridin-2-one-3-carboxylic acid and the 3-carboxamide as well as a short series of 3N-carboxamides, prepared by TPTU/HOBt coupling of primary amines with  $1-(\beta-D-ribofuranosyl)$  pyridin-2-one-3-carboxylic acid, and their evaluation as anti-infective agents is described.

The interest in pyridin-2-one nucleosides stems from the activity exhibited by the pseudobase of these nucleosides. 2-Hydroxynicotinic acid displays inhibitory activity against nicotinate phosphoribosyltransferase (1) and cholesterol and fatty acid synthesis (2), the mechanism of action of which involves conversion to the corresponding ribofuranoside (3). More recently a series of 2-mercapto-3*N*-alkyl-thiocarboxamides have been described by Pagani *et al.* which display significant activity against *Mycobacterium tuberculosis* and *Mycobacterium avium complex* (4).

Based on the results obtained by Pagani *et al.* (4) a series of 1-( $\beta$ -D-ribofuranosyl)pyridin-2-one-3*N*-carboxamides were prepared for evaluation as anti-infectives, using acylated 1-( $\beta$ -D-ribofuranosyl)pyridin-2-one-3-carboxylic acid 3 as the precursor nucleoside.

<sup>\*</sup>Corresponding author.

732 HUNTLEY ET AL.

*Scheme 1.* Reagents and conditions: (i) (a) BSA, CH<sub>3</sub>CN, 1 h (b) 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose, TMSOTf, 24 h, 88% over 2 steps (ii) NH<sub>3</sub>, CH<sub>3</sub>OH, o/n, 100% (iii) CH<sub>3</sub>OH, H<sub>2</sub>SO<sub>4</sub>, reflux, o/n, 45% (iv) NH<sub>3</sub>, CH<sub>3</sub>OH, 24 h, 98% (v) (a) BSA, CH<sub>3</sub>CN, 1 h (b) 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose, TMSOTf, 48 h, 67% over 2 steps (vi) NH<sub>3</sub>, CH<sub>3</sub>OH, 24 h, 52%.

 $1-(\beta-D-Ribofuranosyl)$ pyridin-2-one-3-carboxylic acid **1** was prepared, as previously described (5), by Vorbrüggen coupling of 2-hydroxynicotinic acid **2** with 1,2,3,5-tetra-O-acetyl- $\beta$ -D-ribofuranose with subsequent acyl deprotection. Using the same method the 3-carboxamide derivative (5) **6** was prepared using pyridin-2-one-3-carboxamide **4**, prepared in two steps from 2-hydroxynicotinic acid **2** (Scheme 1).

A short series of **3** N-carboxamides **7–10** (Table 1) were then prepared, in low to moderate yields, by reaction of **3** with a series of primary amines employing O-(1,2-dihydro-2-oxo-1-pyridyl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TPTU) as the coupling agent (Scheme 2).

The pyridin-2-one nucleosides 1, 6 and 7–10 were evaluated against *My-cobacterium tuberculosis* however they exhibited negligible inhibitory activity.

Table 1. HRMS/Microanalysis (MA) Data for the 3N-carboxamide Nucleosides 7–10

Compound	n	HRMS/MA Data
7	2	HRMS (CI, $C_{14}H_{20}N_2O_6$ ): 313.1399 [M + H] <sup>+</sup>
8	3	MA (C <sub>15</sub> H <sub>22</sub> N <sub>2</sub> O <sub>6</sub> ): C, 55.08%; H, 6.96%; N, 8.51%
9	4	MA ( $C_{16}H_{24}N_2O_6 \cdot H_2O$ ): C, 55.01%; H, 7.49%; N, 7.88%
10	5	MA ( $C_{17}H_{26}N_2O_6 \cdot H_2O$ ): C, 54.71%; H, 7.78%; N, 7.41%



REPRINTS

Compounds 1, 6 and 7–10 were also evaluated against a wide range of RNA and DNA viruses including HIV-1, HIV-2, HSV-1, HSV-2, vaccinia, varicella zoster, parainfluenza-3, reovirus-1, sindbis, punta toro, coxsackie B4 and echovirus however, these nucleosides displayed neither cytotoxicity nor any appreciable antiviral activity.

#### ACKNOWLEDGMENTS

Antimycobacterial data were provided by the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) through a research and development contract with the U.S. National Institute of Allergy and Infectious Disease.

#### REFERENCES

- 1. Gaut, Z.N.; Solomon, H.M. J. Pharm. Sci., 1971, 60, 1887–1888.
- 2. Miller, O.N.; Gutiere, M.; Sullivan, J.G. In *Metabolic effects of nicotinic acid and its derivatives*, K.F. Gey and L.A. Carlson (eds). Hans Huber, Bern, **1971**, 609.
- 3. Schwartz, M.A.; Kolis, S.J.; Williams, T.H.; Gabriel, T.F.; Toome, V. *Drug Metab. Dispos.*, **1973**, *1*, 557–564.
- 4. Pagani, G.; Pregnolata, M.; Ubiali, D.; Terrani, M.; Piersimani, C.; Scaglione, F.; Fraschini, F.; Gascon, A.R.; Munoz, J.L.P. *J. Med. Chem.*, **2000**, *43*, 199–204.
- Hanna, N.B.; Joshi, R.V.; Larson, S.B.; Robins, R.K.; Revankar, G.R. *J. Heterocycl. Chem.*, 1989, 26, 1835–1843.



### **Request Permission or Order Reprints Instantly!**

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the U.S. Copyright Office for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on Fair Use in the Classroom.

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our Website User Agreement for more details.

## **Order now!**

Reprints of this article can also be ordered at http://www.dekker.com/servlet/product/DOI/101081NCN100002361